Flavopiridol (Alvocidib)

Catalog No. A10390

Flavopiridol (Alvocidib) is a cyclin-dependent kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia.
  • Zhiyuan Zhao, .et al. CDK9 and SPT5 proteins are specifically required for expression of herpes simplex virus 1 replication-dependent late genes, J Biol Chem, 2017, Sep 15; 292(37): 15489-15500 PMID: 28743741
  • Sami Kukkonen, .et al. HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells, Retrovirology., 2014, 11: 30. PMID: 24742347
Catalog Num A10390
M. Wt 401.8
Formula C21H20ClNO5
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 146426-40-6
Synonyms HMR-1275, L868275
SMILES CN1CC[[email protected]@H]([[email protected]@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
Flavopiridol (Alvocidib) is a cyclin-dependent kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia.
Targets
CDK1 CDK2 CDK4 CDK6 CDK7
40 nM40 nM40 nM40 nM300 nM
In vitro (25°C) DMSO 88 mg/mL (200.77 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 24.89 mL 124.44 mL 248.88 mL
0.5 mM 4.98 mL 24.89 mL 49.78 mL
1 mM 2.49 mL 12.44 mL 24.89 mL
5 mM 0.5 mL 2.49 mL 4.98 mL

*The above data is based on the productmolecular weight 401.8 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.